BEDFORD, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in September and October 2026.
Upcoming Investor Conferences:
Wells Fargo 21st Annual Healthcare Conference:
Date: Thursday, September 10, 2026
Ocular Therapeutix to host investor one-on-one meetings
Location: Boston, MA
Baird 2026 Global Healthcare Conference:
Date: Tuesday, September 15, 2026
Fireside Chat: 10:50 – 11:20 AM EDT
Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO
Location: New York, NY
A live webcast of the Baird fireside chat can be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcasts will be archived for at least 30 days following the presentation.
Upcoming Scientific Conferences:
The Retina Society 59th Annual Scientific Meeting: September 23 – 26, 2026
Los Angeles, CA
- Presentation: Efficacy and Safety of Intravitreal Axitinib Hydrogel (OTX-TKI) in Neovascular Age-related Macular Degeneration: Results from the Phase 3 SOL-1 Superiority Trial
Session: AMD I
Presentation Date/Time: Thursday, September 24, 2026, 11:30 – 11:34 AM PDT
Presenter: Dilsher S. Dhoot, MD
Ophthalmology Futures Forums (OFF) Retina Forum 2026: September 30, 2026
Vienna, Austria
- Presentation: Ocular Therapeutix: Redefining the Retina Experience
Presenter: Nadia K. Waheed, MD, MPH, Chief Medical Officer, Ocular Therapeutix
Euretina Innovation Spotlight (EIS): September 30, 2026
Vienna, Austria
- Presentation Title: Ocular Therapeutix: Redefining the Retina Experience
Presenter: Peter K. Kaiser, MD, Chief Development Officer, Ocular Therapeutix
26th Euretina Congress: October 1 - 4, 2026
Vienna, Austria
- Presentation Title: Efficacy and Safety of Intravitreal Axitinib Hydrogel (OTX-TKI) in Neovascular Age-related Macular Degeneration: Results from the Phase 3 SOL-1 Superiority Trial
Session: AMD/CSC
Session Date/Time: Friday, October 2, 2026, 13:24 – 13:30 PM CEST
Presenter: Adnan Tufail, MBBS, MD, FRCOphth
- Symposium Title: Redefining the Management of nAMD: The Impact of Durability and Sustained Disease Control
Symposium Date/Time: Friday, October 2, 2026, 9:45 – 10:45 AM CEST
Faculty: Arshad M. Khanani, MD, MA, FASRS; Patricio G. Schlottmann, MD; Adnan Tufail, MBBS, MD, FRCOphth; Dilsher S. Dhoot, MD
Exact medical conference presentation times may be subject to change.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.
Follow the Company on its website, LinkedIn, or X.
DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
[email protected]